Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SSY Group ( (HK:2005) ) has shared an update.
SSY Group Limited has announced that its product, Fampridine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This approval marks a significant milestone as it is the first of its kind for PRC entities, potentially enhancing the company’s position in the pharmaceutical market and offering new treatment options for adults with multiple sclerosis.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is involved in creating bulk drugs and has a market focus on providing innovative medical solutions.
Average Trading Volume: 14,512,429
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.91B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money